Participant flow

APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma · Source last updated 2020-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Relapsed or refractory myeloma patients.

   id

   FG000

   title

   AUTO2

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Physician Decision

   3. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Progressive disease

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         12

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         12

      type

      Leukaperesed

   3. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      Started Pre-conditioning Therapy

   4. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      Received Study Treatment

   5. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Screening procedures were performed up to 12 weeks before study treatment administered

recruitment Details

Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients were treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice